HELIXATE FS Rx
Generic Name and Formulations:
Antihemophilic Factor VIII (recombinant) 250 IU, 500 IU, 1000 IU; per bottle; dried concentrate for IV infusion after reconstitution; contains sucrose; preservative-free.
CSL Behring, LLC
Indications for HELIXATE FS:
Prevention and control of hemorrhagic episodes or in order to perform emergency or elective surgery in Hemophilia A patients.
Adults and Children:
Dosage Required (IU) = Body Weight (kg) × Desired % Factor VIII Increase × 0.5. Individualize. Infuse over 5–10minutes if tolerated. Minor hemorrhage: 10–20 IU/kg; may repeat dose if needed. Moderate/major hemorrhage or minor surgery: 15–30 IU/kg; may repeat 1 dose at 12–24hrs if needed. Major/life-threatening hemorrhage, fractures or head trauma: initially 40–50 IU/kg, then 20–25 IU/kg every 8–12hrs. Major surgery: pre-op dose: 50 IU/kg (verify ~100% activity prior to surgery); may repeat after 6–12hrs initially, and for 10–14 days until completely healed.
Mouse or hamster protein sensitivity.
Not for treating von Willebrand's disease. Confirm Factor VIII deficiency prior to treatment. Monitor for development of Factor VIII inhibitors. Pregnancy (Cat.C). Nursing mothers.
Inj site reactions, dizziness, rash, dysgeusia, increased BP, pruritus, depersonalization, GI upset, rhinitis; antibody formation, hypersensitivity reactions.
Single-use bottle—1 (w. diluent)
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments